These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 4282925)

  • 1. In vitro cytotoxicity of normal serum factor(s) on neuraminidase-treated Ehrlich ascites tumor cells and murine leukemia L 1210 cells.
    Sethi KK; Brandis H
    Z Immunitatsforsch Exp Klin Immunol; 1972 May; 143(4):426-9. PubMed ID: 4282925
    [No Abstract]   [Full Text] [Related]  

  • 2. Antigenicity of Ehrlich ascites through neuraminidase treatment of cells.
    Sur P; Roy DK
    Indian J Exp Biol; 1979 Sep; 17(9):953-5. PubMed ID: 544474
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunogenicity of leukemia L1210 cells after neuraminidase treatment.
    Bekesi JG; St Arneault G; Walter L; Holland JF
    J Natl Cancer Inst; 1972 Jul; 49(1):107-18. PubMed ID: 4338766
    [No Abstract]   [Full Text] [Related]  

  • 4. Synergistic cytotoxic effect of macrophages and normal mouse serum on neuraminidase-treated murine leukaemia cells.
    Sethi KK; Brandis H
    Eur J Cancer (1965); 1973; 9(11-12):809-19. PubMed ID: 4613554
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunogenicity of L 1210 murine leukaemia cells after treatment with neuraminidase.
    Bagshawe KD; Currie GA
    Nature; 1968 Jun; 218(5148):1254-5. PubMed ID: 5656653
    [No Abstract]   [Full Text] [Related]  

  • 6. A naturally occurring complement dependent human IgM macroglobulin inhibitory to Ehrlich ascites tumor cells.
    Goff MM; Armentrout SA
    J Clin Lab Immunol; 1982 Dec; 9(3):163-7. PubMed ID: 7166749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of syngeneic, allogeneic and xenogeneic complement with murine leukaemia and carcinoma cells in vitro [proceedings].
    Peeters P; Verloes R; Atassi G; Kanarek L
    Arch Int Physiol Biochim; 1979 Oct; 87(4):836-8. PubMed ID: 93935
    [No Abstract]   [Full Text] [Related]  

  • 8. [Transplantable ascitic tumor derived from a mouse with moloney sarcoma: tumorigenic, antigenic and virologic properties (author's transl)].
    Weiland E; Weiland F
    Z Immunitatsforsch Exp Klin Immunol; 1974 Nov; 148(2):151-61. PubMed ID: 4283271
    [No Abstract]   [Full Text] [Related]  

  • 9. Resistance to Ehrlich ascites tumor in a strain of dystrophic mice.
    Carry PJ; Prescott DM; Ogilvie GK
    Cancer Res; 1979 Jun; 39(6 Pt 1):2139-40. PubMed ID: 445411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transplantability and antigenicity of two sublines of the TA3 tumor.
    Sanford BH; Codington JF; Jeanloz RW; Palmer PD
    J Immunol; 1973 May; 110(5):1233-7. PubMed ID: 4572632
    [No Abstract]   [Full Text] [Related]  

  • 11. Monoclonal antibody-recognizing tumor-associated antigen of DBA/2 mouse lymphoma L1210 and its sublines.
    Fuji H
    Transplant Proc; 1980 Sep; 12(3):388-90. PubMed ID: 6784299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammary tumor virus-associated antigenicity of L-1210 murine leukemia cells.
    Kisielow P; Radzikowski C; Steuden J; Szkudlarek J; Krawczynski K
    Arch Immunol Ther Exp (Warsz); 1971; 19(6):789-99. PubMed ID: 4335186
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of macrophages in the cytotoxic killing of tumour cells in vitro. I. Primary immunization of lymphocytes in vitro for target cell killing and the mechanism of lymphocyte-macrophage cooperation.
    Zembala M; Ptak W; Hanczakowska M
    Immunology; 1973 Oct; 25(4):631-44. PubMed ID: 4356674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer immunity after treatment of Ehrlich tumor with diphtheria toxin.
    Buzzi S; Buzzi L
    Cancer Res; 1974 Dec; 34(12):3481-6. PubMed ID: 4429964
    [No Abstract]   [Full Text] [Related]  

  • 15. Natural cell-mediated cytotoxicity in Ehrlich ascites tumor-bearing mice.
    Olinescu A; Hristescu S; Mazilu E
    Neoplasma; 1983; 30(2):147-52. PubMed ID: 6843720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effectiveness of neuraminidase-treated tumor cells as an immunogen in man and experimental animals with leukemia.
    Bekesi JG; Roboz JP; Holland JF
    Ann N Y Acad Sci; 1976; 277(00):313-31. PubMed ID: 1069551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increase of leukemia L1210 immunogenicity by Vibrio cholerae neuraminidase treatment.
    Bekesi JG; St-Arneault G; Holland JF
    Cancer Res; 1971 Dec; 31(12):2130-2. PubMed ID: 5120303
    [No Abstract]   [Full Text] [Related]  

  • 18. Specific and non-specific immunotherapy of Ehrlich Ascites Carcinoma in mice.
    Jakóbisiak M; Kańtoch M; Lasek W; Dobaczewska H; Obłakowski P
    Folia Biol (Krakow); 1982; 30(3-4):91-7. PubMed ID: 7166197
    [No Abstract]   [Full Text] [Related]  

  • 19. Factors involved in the cytotoxicity of normal guinea pig serum for cells of murine tumor TA3 sublines treated with neuraminidase.
    Hughes RC; Palmer PD; Sanford BH
    J Immunol; 1973 Oct; 111(4):1071-80. PubMed ID: 4728677
    [No Abstract]   [Full Text] [Related]  

  • 20. Supression of growth of Ehrlich ascites tumor cells in mice pretreated with synthetic analogs of trehalose-6,6-dimycolate (cord factor).
    Yarkoni E; Bekierkunst A; Asselineau J; Toubiana R; Toubiana MJ; Lederer E
    J Natl Cancer Inst; 1973 Aug; 51(2):717-20. PubMed ID: 4765386
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.